Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc is on a positive growth trajectory, bolstered by a substantial increase in eligible patient pools due to a recent protocol update, which could enhance enrollment rates for clinical trials significantly. The company is investing heavily in research and development, with a 21% rise in R&D expenses to $14.0 million, indicating commitment to advancing its innovative therapies and strengthening its product pipeline. Additionally, the impactful clinical data recently published on AVIM therapy suggests the potential for improved patient outcomes, which could further attract strategic partnerships and drive future revenue growth.

Bears say

Orchestra BioMed Holdings Inc. has primarily operated at a loss since its establishment, raising concerns about its long-term profitability potential. The company's clinical trials may face extended timelines and escalating costs, with the risk that its product candidates might not demonstrate safety and efficacy, which could inhibit future commercialization efforts. Additionally, there is potential vulnerability regarding key intellectual property, which could jeopardize the protection of its products and limit competitive advantage.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.